ReviewAdvanced drug delivery reviews2016
Bioengineered heparins and heparan sulfates.
Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 124 citations in OpenAlex.
- Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides by a Covalent Catch-and-Release Approach.Angewandte Chemie (International ed. in English) · 2026Article
- Enhancing Birefringence of Sulphates by Polarity Modification in Planar Cations.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins?Research and practice in thrombosis and haemostasis · 2026Article
- Deciphering Age-Dependent ECM Remodelling in Liver: Proteomic Profiling and Its Implications for Aging and Therapeutic Targets.Cell proliferation · 2025Article
- Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery.Biomedicines · 2025Review
- Heparin and Gelatin Co-Functionalized Polyurethane Artificial Blood Vessel for Improving Anticoagulation and Biocompatibility.Bioengineering (Basel, Switzerland) · 2025Article
- A high effective expression of human D-glucuronyl C5-epimerase with dimer structure inFrontiers in microbiology · 2025Article
- Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization.Current protein & peptide science · 2024Article
- Biomedical applications of engineered heparin-based materials.Bioactive materials · 2024Review
- Cloning and Expression of Heparinase Gene from a Novel Strain Raoultella NX-TZ-3-15.Applied biochemistry and biotechnology · 2022Article
- Biocompatibility pathways and mechanisms for bioactive materials:Bioactive materials · 2022Article
- Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.Thrombosis journal · 2021Review
- Bioengineered production of glycosaminoglycans and their analogues.Systems microbiology and biomanufacturing · 2021Article
- High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.Applied microbiology and biotechnology · 2021Article
- Analysis of the Glycosaminoglycan Chains of Proteoglycans.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Review
- Recent advances on glycosyltransferases involved in the biosynthesis of the proteoglycan linkage region.Advances in carbohydrate chemistry and biochemistry · 2021Review
- Glycosaminoglycans.Advances in experimental medicine and biology · 2021Article
- Advances in the preparation and synthesis of heparin and related products.Drug discovery today · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Heparin and heparan sulfates are closely related linear anionic polysaccharides, called glycosaminoglycans, which exhibit a number of important biological and pharmacological activities. These polysaccharides, having complex structures and polydispersity, are biosynthesized in the Golgi of animal cells. While heparan sulfate is a widely distributed membrane and extracellular glycosaminoglycan, heparin is found primarily intracellularly in the granules of mast cells. While heparin has historically received most of the scientific attention for its anticoagulant activity, interest has steadily grown in the multi-faceted role heparan sulfate plays in normal and pathophysiology. The chemical synthesis of these glycosaminoglycans is largely precluded by their structural complexity. Today, we depend on livestock animal tissues for the isolation and the annual commercial production of hundred ton quantities of heparin used in the manufacture of anticoagulant drugs and medical device coatings. The variability of animal-sourced heparin and heparan sulfates, their inherent impurities, the limited availability of source tissues, the poor control of these source materials and their manufacturing processes, suggest a need for new approaches for their production. Over the past decade there have been major efforts in the biotechnological production of these glycosaminoglycans, driven by both therapeutic applications and as probes to study their natural functions. This review focuses on the complex biology of these glycosaminoglycans in human health and disease, and the use of recombinant technology in the chemoenzymatic synthesis and metabolic engineering of heparin and heparan sulfates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.